Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of the drug-drug interaction between triazole antifungals and cystic fibrosis transmembrane conductance regulator modulators in a real-life cohort.

Medical mycology - 7 Mar 2024

Jansen Anouk M E, Eggermont Margot N, Wilms Erik B, Aziz Sami, Reijers Monique, Roukema Jolt, Warris Adilia, Brüggemann Roger J M, van der Meer Renske

Abstract excerpt

Limited data on the clinical management of drug-drug interactions between triazoles and Cystic Fibrosis transmembrane conductance regulator (CFTR) modulators are available. We retrospectively evaluated azole target attainment and dose adaptations in patients from two Dutch CF centres concomitantly receiving triazoles and CFTR modulators. In total, 21 patients with 59 triazole trough concentrations were evaluated....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal Agents
Share to Cystic Fibrosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Mutation

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 38444173
DOI: 10.1093/mmy/myae020
PMCID: PMC10956399

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of the drug-drug interaction between triazole antifungals and cystic fibrosis transmembrane conductance regulator modulators in a real-life cohort.PMID 38444173Read ↗

Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®.Semantic proximity Read ↗

Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications.Semantic proximity Read ↗

Triazole resistance surveillance in Aspergillus fumigatus.Semantic proximity Read ↗

Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacySemantic proximity Read ↗

Therapeutic drug monitoring of voriconazole.Semantic proximity Read ↗

Bibliometric analysis of literature on antifungal triazole resistance: 1980 – 2015Semantic proximity Read ↗

Use of CFTR modulators in special populations, part 3: Solid organ transplant.Semantic proximity Read ↗

Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.Semantic proximity Read ↗

Performance of Molecular Approaches for Aspergillus Detection and Azole Resistance Surveillance in Cystic FibrosisSemantic proximity Read ↗

Triazole resistance in Aspergillus fumigatus isolates from patients with cystic fibrosis in ItalySemantic proximity Read ↗

Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Semantic proximity Read ↗

Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.